Sunesis: Looking for the hotspots By Ilan Zipkin
Staff Writer

The first generation of biotechnology companies began with a focus on proteins as therapeutics, for example monoclonal antibodies, enzymes or hormones. The lesson from pharmaceutical companies, however, is that small organic molecules make the best drugs due to oral bioavailability and pharmacokinetic characteristics. Sunesis Pharmaceuticals Inc. plans to bring biotechnology full circle by discovering small molecules that target protein-protein interactions as a means to replace established protein biologics with oral drugs.